Aquestive Therapeutics, Inc. (AQST)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$5.34-0.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AQST
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 80.8% |
| Our one-year growth estimate | diamond | 18.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 62.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
AQST — credit agreement
Dated 2026-05-13
Entry into a Material Definitive Agreement. Credit Agreement and Guaranty On May 12, 2026 (the “Effective Date”), Aquestive Therapeutics, Inc. (the “Company”) entered into a five-year term loan facility of up to $150.0 million (the “Term Loan”), consisting of a term loan in an aggregate principal amount of $55.0 million that was funded on the Effective Date (the “Tranche A Term Loan”), a term loan in an aggregate principal amount of $20.0 million available subject to certain terms and conditi…
Why it matters: Confirming revenue guidance would indicate the company is on track to meet its financial goals. This can impact investor confidence.
Supportive ifThe company reaffirms its revenue guidance of $46-$50 million for 2026.
Worry ifThe company lowers its revenue guidance from $46-$50 million.
Why it matters: Managing EBITDA loss is key for financial health. It reflects cost control efforts.
Supportive ifEBITDA loss reported within the range of $30-$35M for 2026.
Worry ifThe EBITDA loss for 2026 is over $35M.
Why it matters: Meeting revenue targets shows the company is on track for its $46-$50M goal for 2026.
Supportive ifQ2 2026 revenue reported at or above $14.45M.
Worry ifQ2 2026 revenue reported below $14.45M.
Why it matters: Hitting this target shows the company is on track for growth and financial health.
Supportive ifThe company reports total revenue of $46 million or more for 2026.
Worry ifThe company reports total revenue below $46 million for 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$191 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $581 loss on $10,000 · 5.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,061 loss on $10,000 · 60.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The FDA's feedback is important for Anaphylm's approval. It could affect the company's future.
Watch forThe FDA gives good feedback on the resubmitted Anaphylm NDA.
Also watch forThe FDA issues further concerns or a negative response to the resubmission.
Why it matters: Results from AQST-108 studies could affect the company's growth plans and future products.
Watch forThe company reports positive results from the next AQST-108 clinical trial.
Also watch forThe company reports bad results or safety problems from the AQST-108 clinical trial.
Why it matters: The resubmission is crucial for Anaphylm's approval. Success could lead to market entry for a new treatment.
Supportive ifThe NDA is submitted on or before September 30, 2026.
Worry ifThe NDA resubmission is delayed beyond Q3 2026.
Why it matters: Good FDA feedback would help with resubmission. It would also raise confidence in Anaphylm's approval.
Supportive ifThe FDA gives positive feedback on studies about human factors and how the drug works.
Worry ifFDA asks for more studies or data before looking at the NDA.
Why it matters: Continued revenue growth is key to achieving the $46-$50 million target for 2026. This reflects the company's financial health.
Supportive ifQ2 2026 revenue shows an increase compared to Q1 2026, supporting the growth trajectory.
Worry ifQ2 2026 revenue declines or does not meet the previous quarter's revenue.
Why it matters: The new debt facility could extend the company's cash runway for Anaphylm's launch.
Supportive ifThe company says the $150 million debt facility helps improve its cash runway.
Worry ifThe company faces cash flow issues despite the new debt facility.
Why it matters: Earnings will provide insights into revenue growth and cost management.
Watch forEarnings report shows revenue growth and improved EBITDA loss.
Also watch forThe earnings report shows lower revenue. It also shows a bigger EBITDA loss.